Patients with thyrotoxicosis who developed thyroid storm died at nearly double the rate as those without thyroid storm, ...

“We believe that the NCE exclusivity strategy is an attractive approach if istaroxime receives FDA approval in cardiogenic shock,” said ... of the SERCA2a calcium pump on the sarcoplasmic ...

2 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany ...

Specialists are debating the best approach in cardiogenic shock after a new analysis of data comparing Impella with ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have shown that increasing survival rates in cardiogenic shock is challenging.

Background: There is currently a lack of easy-to-use tools for assessing the severity of cardiogenic shock (CS) patients. This study aims to develop a nomogram for evaluating severity in CS patients ...

The patent, set to extend into at least January 2031, pertains to an intragastric balloon system designed to be swallowed in capsule form and naturally excreted after deflation. The innovative system ...

In patients with cardiogenic shock (CS), a percutaneous microaxial ventricular assist device (Impella, Abiomed, Danvers, MA) is a choice for temporary mechanical circulatory support. Given the high ...